SG11201408521WA - Use of ferric citrate in the treatment of chronic kidney disease patients - Google Patents
Use of ferric citrate in the treatment of chronic kidney disease patientsInfo
- Publication number
- SG11201408521WA SG11201408521WA SG11201408521WA SG11201408521WA SG11201408521WA SG 11201408521W A SG11201408521W A SG 11201408521WA SG 11201408521W A SG11201408521W A SG 11201408521WA SG 11201408521W A SG11201408521W A SG 11201408521WA SG 11201408521W A SG11201408521W A SG 11201408521WA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- rule
- iron
- kidney disease
- chronic kidney
- Prior art date
Links
- 208000020832 chronic kidney disease Diseases 0.000 title abstract 3
- 229960002413 ferric citrate Drugs 0.000 title abstract 3
- NPFOYSMITVOQOS-UHFFFAOYSA-K iron(III) citrate Chemical compound [Fe+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NPFOYSMITVOQOS-UHFFFAOYSA-K 0.000 title abstract 3
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 abstract 8
- 229910052742 iron Inorganic materials 0.000 abstract 4
- 210000002966 serum Anatomy 0.000 abstract 3
- 239000003173 antianemic agent Substances 0.000 abstract 2
- 229940125367 erythropoiesis stimulating agent Drugs 0.000 abstract 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 abstract 1
- 102000008857 Ferritin Human genes 0.000 abstract 1
- 108050000784 Ferritin Proteins 0.000 abstract 1
- 238000008416 Ferritin Methods 0.000 abstract 1
- 102000001554 Hemoglobins Human genes 0.000 abstract 1
- 108010054147 Hemoglobins Proteins 0.000 abstract 1
- 206010022971 Iron Deficiencies Diseases 0.000 abstract 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 abstract 1
- 102000004338 Transferrin Human genes 0.000 abstract 1
- 108090000901 Transferrin Proteins 0.000 abstract 1
- 238000010521 absorption reaction Methods 0.000 abstract 1
- 208000007502 anemia Diseases 0.000 abstract 1
- 229960000074 biopharmaceutical Drugs 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 229910052698 phosphorus Inorganic materials 0.000 abstract 1
- 239000011574 phosphorus Substances 0.000 abstract 1
- 239000012581 transferrin Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/295—Iron group metal compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Inorganic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261662565P | 2012-06-21 | 2012-06-21 | |
| US201361757229P | 2013-01-28 | 2013-01-28 | |
| US201361800618P | 2013-03-15 | 2013-03-15 | |
| US201361801050P | 2013-03-15 | 2013-03-15 | |
| PCT/US2013/047134 WO2013192565A2 (en) | 2012-06-21 | 2013-06-21 | Use of ferric citrate in the treatment of chronic kidney disease patients |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201408521WA true SG11201408521WA (en) | 2015-01-29 |
Family
ID=49769729
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201408521WA SG11201408521WA (en) | 2012-06-21 | 2013-06-21 | Use of ferric citrate in the treatment of chronic kidney disease patients |
| SG10201805177PA SG10201805177PA (en) | 2012-06-21 | 2013-06-21 | Use of ferric citrate in the treatment of chronic kidney disease patients |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201805177PA SG10201805177PA (en) | 2012-06-21 | 2013-06-21 | Use of ferric citrate in the treatment of chronic kidney disease patients |
Country Status (17)
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011011541A1 (en) | 2009-07-21 | 2011-01-27 | Henry Trong Le | Ferric citrate dosage forms |
| TWI653043B (zh) * | 2012-12-20 | 2019-03-11 | 瑞士商伊蘭科動物健康公司 | 新用途 |
| TR201909355T4 (tr) | 2013-06-05 | 2019-07-22 | Tricida Inc | Oral uygulama için proton bağlayıcı polimerler. |
| ES2856261T3 (es) * | 2013-10-01 | 2021-09-27 | Fresenius Medical Care Deutschland Gmbh | Método y aparatos para determinar una pérdida diaria de hierro de un paciente |
| EP3747432A1 (en) * | 2013-11-04 | 2020-12-09 | Keryx Biopharmaceuticals, Inc. | Ferric citrate for reducing cardiac failure in chronic kidney disease patients |
| WO2015110968A1 (en) * | 2014-01-23 | 2015-07-30 | Lupin Limited | Pharmaceutical grade ferric citrate and method for its production |
| WO2015198304A1 (en) | 2014-06-22 | 2015-12-30 | Dexcel Pharma Technologies Ltd. | Pharmaceutical compositions comprising ferric citrate and methods for the production thereof |
| AU2015360413B2 (en) | 2014-12-10 | 2021-07-08 | Tricida, Inc. | Proton-binding polymers for oral administration |
| KR20170123664A (ko) * | 2015-03-04 | 2017-11-08 | 케릭스 바이오파마슈티컬스 인코포레이티드 | 철-결핍성 빈혈의 치료에서 구연산철의 용도 |
| CN104688706B (zh) * | 2015-04-01 | 2017-07-14 | 成都欣捷高新技术开发有限公司 | 一种高载药量、快速溶出的枸橼酸铁组合物及其制备方法 |
| WO2016162794A1 (en) * | 2015-04-08 | 2016-10-13 | Leiutis Pharmaceuticals Pvt Ltd | Pharmaceutical compositions of ferric citrate |
| WO2016162888A1 (en) * | 2015-04-09 | 2016-10-13 | Actavis Group Ptc Ehf. | Process for preparing pharmaceutical grade ferric citrate |
| US20190209607A1 (en) | 2016-05-06 | 2019-07-11 | Tricida, Inc. | Compositions for treating acid-base disorders |
| US20210085711A1 (en) | 2017-09-19 | 2021-03-25 | Japan Tobacco Inc. | Use of ferric citrate in prevention and/or treatment of iron-deficiency anemia in hypermenorrhea patient and/or patient suffering from hypermenorrhea-associated gynecologic disease |
| AU2018360867B2 (en) | 2017-11-03 | 2024-12-12 | Tricida, Inc. | Compositions for and method of treating acid-base disorders |
| WO2019236639A1 (en) * | 2018-06-04 | 2019-12-12 | Tricida, Inc. | Method of treating acid-base disorders |
| MX2021004640A (es) | 2018-10-29 | 2021-05-28 | Pharmacosmos Holding As | Tratamiento de la deficiencia de hierro con carboximaltosa ferrica. |
| WO2022150623A1 (en) | 2021-01-08 | 2022-07-14 | Akebia Therapeutics, Inc. | Compounds and composition for the treatment of anemia |
| TW202313072A (zh) | 2021-05-27 | 2023-04-01 | 美商凱立克斯生物製藥股份有限公司 | 檸檬酸鐵之兒科調配物 |
| CN115024495B (zh) * | 2022-06-27 | 2024-03-22 | 北京金康普食品科技有限公司 | 改善肾病患者钙磷代谢的营养组合物及其应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1230118A (zh) * | 1996-07-19 | 1999-09-29 | 日研化学株式会社 | 高磷血症治疗剂 |
| US5753706A (en) * | 1996-12-16 | 1998-05-19 | Hsu; Chen Hsing | Methods for treating renal failure |
| US8093423B2 (en) | 2003-02-19 | 2012-01-10 | Globoasia, Llc | Pharmaceutical-grade ferric organic compounds, uses thereof and method of making same |
| TWI335218B (en) | 2003-02-19 | 2011-01-01 | Panion & Bf Biotech Inc | Ferric organic compounds, uses thereof and methods of making same |
| CN1600302A (zh) * | 2003-09-22 | 2005-03-30 | 宝龄富锦生技股份有限公司 | 含有柠檬酸铁的医药组合物以及药用级柠檬酸铁及其制法和含有药用级柠檬酸铁的膳食营养品 |
| US20060134227A1 (en) * | 2004-12-22 | 2006-06-22 | Bortz Jonathan D | Compositions including iron |
| MX2008002360A (es) | 2005-08-18 | 2008-04-29 | Globoasia Llc | Compuestos organicos ferricos grado farmaceutico, uso de los mismos y metodos para elaborar los mismos. |
| KR20140117678A (ko) * | 2006-01-06 | 2014-10-07 | 루이트폴드 파머수티컬스, 인코퍼레이티드 | 철을 투여하기 위한 방법 및 조성물 |
| JP2009525276A (ja) | 2006-01-30 | 2009-07-09 | グロボアジア エルエルシー | 慢性腎疾患の治療法 |
| WO2011011541A1 (en) | 2009-07-21 | 2011-01-27 | Henry Trong Le | Ferric citrate dosage forms |
-
2013
- 2013-06-21 MX MX2014015615A patent/MX2014015615A/es unknown
- 2013-06-21 SG SG11201408521WA patent/SG11201408521WA/en unknown
- 2013-06-21 EP EP13807102.2A patent/EP2863906B1/en active Active
- 2013-06-21 KR KR1020207024260A patent/KR20200103855A/ko not_active Ceased
- 2013-06-21 EP EP20163104.1A patent/EP3730136B1/en active Active
- 2013-06-21 CA CA2876982A patent/CA2876982A1/en not_active Abandoned
- 2013-06-21 CN CN201380044271.0A patent/CN104884055A/zh active Pending
- 2013-06-21 SG SG10201805177PA patent/SG10201805177PA/en unknown
- 2013-06-21 HK HK16102352.0A patent/HK1214503A1/zh unknown
- 2013-06-21 DK DK20163104.1T patent/DK3730136T3/da active
- 2013-06-21 PL PL20163104.1T patent/PL3730136T3/pl unknown
- 2013-06-21 KR KR1020157001458A patent/KR102150135B1/ko active Active
- 2013-06-21 CN CN202110644193.4A patent/CN113244209A/zh active Pending
- 2013-06-21 EP EP23219273.2A patent/EP4335436A3/en not_active Withdrawn
- 2013-06-21 EA EA201590062A patent/EA201590062A1/ru unknown
- 2013-06-21 BR BR112014032049A patent/BR112014032049A2/pt not_active IP Right Cessation
- 2013-06-21 ES ES20163104T patent/ES2970050T3/es active Active
- 2013-06-21 ES ES13807102T patent/ES2796254T3/es active Active
- 2013-06-21 WO PCT/US2013/047134 patent/WO2013192565A2/en active Application Filing
- 2013-06-21 JP JP2015518623A patent/JP2015535209A/ja active Pending
- 2013-06-21 US US13/924,332 patent/US20130345303A1/en not_active Abandoned
- 2013-06-21 AU AU2013278000A patent/AU2013278000A1/en not_active Abandoned
-
2014
- 2014-04-25 US US14/262,465 patent/US20140234416A1/en not_active Abandoned
- 2014-10-24 US US14/523,656 patent/US20150079168A1/en not_active Abandoned
- 2014-12-18 IL IL236356A patent/IL236356A0/en unknown
-
2018
- 2018-04-10 JP JP2018075243A patent/JP2018138562A/ja active Pending
- 2018-05-08 AU AU2018203205A patent/AU2018203205B2/en not_active Ceased
-
2020
- 2020-02-25 JP JP2020029756A patent/JP2020100638A/ja active Pending
-
2022
- 2022-02-10 JP JP2022019167A patent/JP2022070945A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201408521WA (en) | Use of ferric citrate in the treatment of chronic kidney disease patients | |
| SG11201908391XA (en) | Methods for modulating an immune response | |
| SG11201909955XA (en) | Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies | |
| SG11201807176XA (en) | TGFß1-BINDING IMMUNOGLOBULINS AND USE THEREOF | |
| SG11201408318RA (en) | Compositions and methods for transmucosal absorption | |
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
| SG11201811564QA (en) | Methods of treating ovarian cancer | |
| SG11201407859YA (en) | Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists | |
| SG11201407851RA (en) | Synthesis of pyrrolo [2, 3 - b] pyridines | |
| SG11201804161VA (en) | Compositions comprising bacterial strains | |
| SG11201810927QA (en) | Pd-l1-specific antibodies and methods of using the same | |
| SG11201804373VA (en) | Compositions and methods for immunooncology | |
| SG11201408780XA (en) | Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof | |
| SG11201804729RA (en) | Methods and compositions for treating a serpinc1-associated disorder | |
| SG11201408095XA (en) | Fibroblast growth factor 21 proteins | |
| SG11201407655TA (en) | Therapeutic uses of fibroblast growth factor 21 proteins | |
| SG11201810628XA (en) | Nasal pharmaceutical compositions with a porous excipient | |
| SG11201901961SA (en) | Methods of using a bispecific antibody that recognizes coagulation factor ix and/or activated coagulation factor ix and coagulation factor x and/or activated coagulation factor x | |
| SG11201408124PA (en) | Differentiation of human embryonic stem cells into pancreatic endocrine cells | |
| SG11201407537YA (en) | Mutant selectivity and combinations of a phosphoinositide 3 kinase inhibitor compound and chemotherapeutic agents for the treatment of cancer | |
| SG11201407508RA (en) | Encoding and decoding based on blending of sequences of samples along time | |
| SG11201808106YA (en) | Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation | |
| SG11201403106SA (en) | Anti-phf-tau antibodies and their uses | |
| SG11201807677YA (en) | Antibodies to cd40 with enhanced agonist activity | |
| SG11201804704PA (en) | Compositions and methods for decreasing tau expression |